Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Xing-Nong YeInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and ;Department of Hematology, The fourth Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China

Xin-Ping ZhouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Ju-Ying WeiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Gai-Xiang XuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Ying LiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Li-Ping MaoInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Jian HuangInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;Department of Hematology, The fourth Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China

Yan-Ling RenInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Chen MeiInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Jing-Han WangInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Yin-Jun LouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Li-Ya MaInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Wen-Juan YuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Li YeInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Li-Li XieInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Yin-Wan LuoInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Chao HuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Lin-Mei NiuInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Min-Hua DouInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and

Jie JinInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China,

Hong-Yan TongInstitute of Hematology, Department of Hematology, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, ;MDS Center, The first Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China, and Correspondence[email protected]

show all

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Articles from other publishers (19)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms

Citations (23)

Read on this site (4)

Articles from other publishers (19)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date